BIOCRYST director awarded RSUs and stock options

BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received equity awards as part of non‑employee director compensation.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Jill C. Milne received equity awards as part of non‑employee director compensation. She was granted 15,294 shares of Common Stock as Restricted Stock Units that will vest on the first anniversary of the June 11, 2026 grant date.

She also received an automatic grant of options to purchase 33,540 shares of Common Stock at an exercise price of $8.50 per share, exercisable until June 11, 2036. Following the RSU grant, she holds 31,938 Common Stock shares directly. These are compensation-related awards rather than open-market purchases.

Insider Trade Summary

Grant/Award: 48,834 shares

Grant/Award 2 txns

Insider Milne Jill C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Automatic Stock Option Grant	33,540	$0.00	$0.00
Grant/Award	Common Stock	15,294	$0.00	$0.00

Holdings After Transaction: Automatic Stock Option Grant — 33,540 contracts (Direct); Common Stock — 31,938 shares (Direct)

Footnotes (2)

1. F1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
2. F2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

Key Figures

RSU grant: 15,294 shares Stock options granted: 33,540 options Option exercise price: $8.50 per share +2 more

5 metrics

RSU grant 15,294 shares Restricted Stock Units granted June 11, 2026; vest on first anniversary

Stock options granted 33,540 options Automatic non-employee director stock option grant on June 11, 2026

Option exercise price $8.50 per share Exercise price for 33,540 stock options granted June 11, 2026

Option expiration June 11, 2036 Expiration date of automatic non-employee director stock options

Shares held after grant 31,938 shares Common Stock directly owned after RSU grant on June 11, 2026

Key Terms

Restricted Stock Units, Non-Employee Director Compensation Policy, Automatic Stock Option Grant, stock options

4 terms

Restricted Stock Units financial

"Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Non-Employee Director Compensation Policy financial

"Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended"

Automatic Stock Option Grant financial

"Automatic Stock Option Grant, transaction type derivative with underlying Common Stock"

stock options financial

"Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did BIOCRYST (BCRX) director Jill C. Milne receive?

Jill C. Milne received 15,294 Restricted Stock Units and options on 33,540 shares of Common Stock. Both awards were automatic non-employee director grants under the company’s Director Compensation Policy as part of her board compensation package.

When do Jill C. Milne’s new BIOCRYST (BCRX) Restricted Stock Units vest?

The 15,294 Restricted Stock Units granted to Jill C. Milne vest on the first anniversary of the June 11, 2026 grant date. Vesting is tied to continued director service under the company’s Non-Employee Director Compensation Policy.

What is the exercise price and term of Jill C. Milne’s new BIOCRYST (BCRX) stock options?

Her automatic stock option grant covers 33,540 shares of Common Stock at an exercise price of $8.50 per share. These options were granted June 11, 2026 and are scheduled to expire on June 11, 2036, if not exercised earlier.

How many BIOCRYST (BCRX) shares does Jill C. Milne hold after the Form 4 transactions?

After the June 11, 2026 Restricted Stock Unit grant, Jill C. Milne directly holds 31,938 shares of BIOCRYST Common Stock. She also holds options covering 33,540 additional shares, which are exercisable at $8.50 per share through June 11, 2036.

Were Jill C. Milne’s BIOCRYST (BCRX) equity awards open-market purchases?

No. The Form 4 shows the awards as automatic grants under the Non-Employee Director Compensation Policy. They are compensation-related RSUs and stock options, not open-market share purchases or sales, and carry a transaction code A for grant or award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milne Jill C.

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		15,294(1)	A	$0	31,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Automatic Stock Option Grant(2)	$8.5	06/11/2026		A		33,540		06/11/2027	06/11/2036	Common Stock	33,540	$0	33,540	D

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

	/s/ Alane P. Barnes, by power of attorney	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)